Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ensysce BiosciencesENSC +4.03%23 EV-to-EBITDA is -0.30 as of Jul. 14, 2026. GuruFocus rates ENSC with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 397 Biotechnology companies, Ensysce Biosciences ranks worse than 251888.92% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ensysce Biosciences's enterprise value is $3.53 Mil.
Ensysce Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-11.76 Mil. Therefore, Ensysce Biosciences's EV-to-EBITDA for today is -0.30.
The historical rank and industry rank for Ensysce Biosciences's EV-to-EBITDA or its related term are showing as below:
ENSC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.3 Med: 0 Max: 0
Current: -0.3
ENSC's EV-to-EBITDA is ranked worse than 100% of 397
companies
in the Biotechnology industry
Industry Median: 12.31
vs ENSC: -0.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ensysce Biosciences's PE Ratio (TTM) for today is calculated as:
Ensysce Biosciences's share price for today is $0.2838.
Ensysce Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.350.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Ensysce Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ensysce Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ensysce Biosciences EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ensysce Biosciences's EV-to-EBITDA falls into.
Ensysce Biosciences's current Enterprise Value is $3.53 Mil.
Ensysce Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ensysce Biosciences (ENSC) has a EV-to-EBITDA of -0.30 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ensysce Biosciences. According to the industry distribution chart, Ensysce Biosciences ranks #999999 out of 397 companies in the Biotechnology industry.
Is Ensysce Biosciences' EV-to-EBITDA too high?
Ensysce Biosciences' current EV-to-EBITDA is -0.30. Based on the distribution chart, Ensysce Biosciences ranks #999999 out of 397 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ensysce Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Ensysce Biosciences' EV-to-EBITDA compare to RNAZ and ALZN?
According to the Biotechnology industry distribution chart, Ensysce Biosciences ranks #999999 out of 397 companies for EV-to-EBITDA. This places Ensysce Biosciences in the lower half of its industry. The industry median EV-to-EBITDA is 12.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.31, based on 397 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ensysce Biosciences. For the Biotechnology industry, the median EV-to-EBITDA is 12.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ensysce Biosciences's current EV-to-EBITDA is -0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ensysce Biosciences stock overvalued right now?
Ensysce Biosciences (ENSC) has a current EV-to-EBITDA of -0.30. The current EV-to-EBITDA is -0.30. Ensysce Biosciences' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ensysce Biosciences (ENSC), the current EV-to-EBITDA is -0.30 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
23GF Score
Get the complete analysis for ENSC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENSC has been successfully added to your 
